ROS1 Gene Rearrangement
7
1
2
1
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 85/100
14.3%
1 terminated out of 7 trials
50.0%
-36.6% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 1 completed trials
Clinical Trials (7)
Study of Crizotinib for ROS1 and MET Activated Lung Cancer
Ceritinib and Everolimus in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIB-IV Non-small Cell Lung Cancer
REPotrectinib in ROS1-positive Non-small Cell Lung Cancer Patients With Active Brain mEtastasis
Real-world Observational Study of Targeted Therapy in Patients With Advanced ROS1-positive NSCLC
Brigatinib and Binimetinib in Treating Patients With Stage IIIB-IV ALK or ROS1-Rearranged Non-small Cell Lung Cancer
Pembrolizumab, Lenvatinib and Chemotherapy After TKIs in NSCLC
X-396 Capsule in Advanced NSCLC Patients With ROS1 Gene Rearrangement